Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$18.59 USD
+0.10 (0.54%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.58 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RCKT 18.59 +0.10(0.54%)
Will RCKT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCKT
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Other News for RCKT
Rocket Pharmaceuticals files automatic mixed securities shelf
Rocket Pharmaceuticals (RCKT) Receives a Buy from Bank of America Securities
Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Zymeworks (ZYME) and Rocket Pharmaceuticals (RCKT)
Solid Clinical Progress and Strong Financial Position Reinforce Buy Rating for Rocket Pharmaceuticals
Analysts Offer Insights on Healthcare Companies: American Well (AMWL), Rocket Pharmaceuticals (RCKT) and Relay Therapeutics (RLAY)